JP2023526505A - 急性腎障害を治療するための方法および組成物 - Google Patents

急性腎障害を治療するための方法および組成物 Download PDF

Info

Publication number
JP2023526505A
JP2023526505A JP2022571179A JP2022571179A JP2023526505A JP 2023526505 A JP2023526505 A JP 2023526505A JP 2022571179 A JP2022571179 A JP 2022571179A JP 2022571179 A JP2022571179 A JP 2022571179A JP 2023526505 A JP2023526505 A JP 2023526505A
Authority
JP
Japan
Prior art keywords
calcium
inhibitor
aki
cells
intracellular calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526505A5 (enExample
Inventor
エー． スタウダーマン，ケネス
ダン，マイケル
ヘッバール，スダルシャン
レーニー，レイチェル
Original Assignee
カルシメディカ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カルシメディカ，インク． filed Critical カルシメディカ，インク．
Publication of JP2023526505A publication Critical patent/JP2023526505A/ja
Publication of JP2023526505A5 publication Critical patent/JP2023526505A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022571179A 2020-05-20 2021-05-19 急性腎障害を治療するための方法および組成物 Pending JP2023526505A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027800P 2020-05-20 2020-05-20
US63/027,800 2020-05-20
PCT/US2021/033237 WO2021236820A1 (en) 2020-05-20 2021-05-19 Methods and compositions for treating acute kidney injury

Publications (2)

Publication Number Publication Date
JP2023526505A true JP2023526505A (ja) 2023-06-21
JP2023526505A5 JP2023526505A5 (enExample) 2024-05-27

Family

ID=76444616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571179A Pending JP2023526505A (ja) 2020-05-20 2021-05-19 急性腎障害を治療するための方法および組成物

Country Status (7)

Country Link
US (1) US20230226058A1 (enExample)
EP (1) EP4153179A1 (enExample)
JP (1) JP2023526505A (enExample)
CN (1) CN116261468A (enExample)
AU (1) AU2021273811A1 (enExample)
CA (1) CA3179405A1 (enExample)
WO (1) WO2021236820A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
TWI771269B (zh) 2015-02-27 2022-07-21 美商鈣系醫藥公司 胰腺炎治療
CA3172249A1 (en) 2020-03-20 2021-09-23 Calcimedica, Inc. Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
JP7791898B2 (ja) 2020-11-13 2025-12-24 カルシメディカ，インク． Ｃｒａｃチャネル阻害剤の合成の改善

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506553A (ja) * 2015-02-27 2018-03-08 カルシメディカ，インク． 膵炎処置
WO2020072942A1 (en) * 2018-10-04 2020-04-09 The Trustees Of Indiana University Methods to treat renal disorders using calcium channel inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078995A2 (en) 2003-03-04 2004-09-16 Neurogenetics, Inc. Methods of modulating and of identifying agents that modulate intracellular calcium
EP1984400B1 (en) 2006-01-05 2012-11-28 Immune Disease Institute, Inc. Regulators of nfat
CN107207431B (zh) * 2015-01-13 2021-02-09 维夫雷昂生物科学有限责任公司 Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506553A (ja) * 2015-02-27 2018-03-08 カルシメディカ，インク． 膵炎処置
WO2020072942A1 (en) * 2018-10-04 2020-04-09 The Trustees Of Indiana University Methods to treat renal disorders using calcium channel inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Public summary of opinion on orphan designation N-(5-(6-chloro-2,2-difluorobenzo[d][1,3]dioxol-5-yl", EUROPEAN MEDICINES AGENCY, JPN6025026328, 2016, pages 1 - 5, ISSN: 0005816530 *
ANN EMERG MED, vol. Vol. 74, No. 4, Suppl., JPN6025026325, 2019, pages 138 - 139, ISSN: 0005816529 *
J CLIN INVEST, vol. 80, no. 5, JPN6025026327, 1987, pages 1232 - 1237, ISSN: 0005816532 *
J CLIN INVEST, vol. 91, no. 5, JPN6025026326, 1993, pages 2281 - 2287, ISSN: 0005816531 *

Also Published As

Publication number Publication date
CA3179405A1 (en) 2021-11-25
WO2021236820A1 (en) 2021-11-25
AU2021273811A1 (en) 2022-12-22
EP4153179A1 (en) 2023-03-29
US20230226058A1 (en) 2023-07-20
CN116261468A (zh) 2023-06-13

Similar Documents

Publication Publication Date Title
US20230226058A1 (en) Methods and compositions for treating acute kidney injury
JP7066768B2 (ja) 細胞内カルシウムを調節する化合物
US9434747B2 (en) Methods of treating diabetes
US10478435B2 (en) Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury
AU2016224993B2 (en) Pancreatitis treatment
US12544371B2 (en) Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
DK2441457T3 (en) SALTS OF SUBSTITUTED-bicyclo PYRAZOLONAZODERIVATER, PROCESS FOR PREPARATION THEREOF AND USE
WO2011093501A1 (ja) Ｇｐｒ１１９作動薬
WO2013112932A1 (en) Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2013071693A1 (zh) 噁二唑类化合物及其制备方法、药物组合物及其用途
KR20240116482A (ko) 과혈당증 및 2형 당뇨병 치료를 위한 (r)-2-(tert-부틸아미노)-1-(5-플루오로피리딘-3-일)-에탄-1-올 헤미-타르트레이트 염의 결정질 형태
US20250120969A1 (en) Methods and compositions for treating inflammation injury in the lungs
CN107708695A (zh) 用于治疗或预防肺高血压的组合物和方法
EP4073069B1 (en) Aromatic amido derivatives as lpa receptor 2 inhibitors
WO2026096796A1 (en) Methods for treating acute pancreatitis
HK40091216A (en) Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
JP2001192375A (ja) オキシイミノアルカン酸誘導体の結晶
JP2002097139A (ja) オキシイミノアルカン酸誘導体の結晶を含有する医薬
HK1154503B (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
KR20090010093A (ko) 피리딜메틸피페라진 및 피리딜메틸피페리딘 유도체의 ｎ-옥사이드

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260717